¹ú²úÖ÷²¥

Sims, J. D., Taguiam, J. M., Alonso-Valenteen, F., Markman, J., Agadjanian, H., Chu, D., Lubow, J., Abrol, R., Srinivas, D., Jain, A., Han, B., Qu, Y., Mirzadehgan, P., Hwang, J-Y., Rentsendorj, A., Chung, A., Lester, J., Karlan, B. Y., Gray, H. B., Gross, Z., Giuliano, A., Cui, X., Medina-Kauwe L. K. (2018). Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics. Journal of Controlled Release, 271,127-138. https://doi.org/10.1016/j.jconrel.2017.12.024

Beach, J.A., Aspuria, P-J. P., Cheon, D-J., Lawrenson, Agadjanian, H., Walsh, C., Karlan, B.Y., & Orsulic, S. (2015). Sphingosine kinase 1 is required for TGF-? mediated fibroblastto-myofibroblast differentiation in ovarian cancer. Oncotarget, 7 (4), 4167-4182.

Cohen, J. G., Prendergast, E., Geddings, J. E., Walts, A. E., Agadjanian, H., Hisada, Y., Karlan B.Y., Mackman N., & Walsh, C. S. (2017). Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. Gynecologic Oncology, 146(1), 146-152. doi:10.1016/j.ygyno.2017.04.021

Liu, Z., Beach, J.A., Agadjanian, H., Jia, D., Aspuria, P-J., Karlan, B.Y., & Orsulic, S. (2015). Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecologic Oncology, 139, 394-400. DOI:10.1016/j.ygyno.2015.08.026 · 3.77

Taylor-Harding, B., Aspuria, P-J, Agadjanian, H., Cheon, D-J, & Wiedemeyer, W.R. (2014). CyclinE and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget, 6 (2), 696-714.

Diaz, E., Agadjanian, H., Nassanian, H., Walts, A., Miller, C., Karlan, B., Osulic, S., & Walsh C. (2013). PI3K pathway activation, thromboembolism and survival in ovarian cancer cell carcinoma. Gynecologic Oncology, 130(1) e.128. DOI:10.1016/j.ygyno.2013.04.367

Agadjanian, H., Chu, D., Hwang, J.Y., Wachsmann-Hogiu, S., Rentsendorj, A., Song, L., Valluripalli, V., Lubow, J., Ma, J., Sharifi, B., Farkas, D.L.,& Medina-Kauwe, L.K. (2012). Chemotherapy targeting by DNA capture in viral protein particles. Nanomedicine, 7(3), 335-352. DOI: 10.2217/nnm.11.104

Taylor-Harding, B., Agadjanian, H., Nassanian, H., Kwon, S., Guo, X., Miller, C., & Karlan, B.Y. Orsulic, S., and Walsh, C.S. (2012). Indole-3-carbinol synergistically sensitizes ovarian cancer cells to bortezomib treatment. British Journal of Cancer, 106, 333 – 343.

Fleming, N. D., Agadjanian, H., Nassanian, H., Miller, C. W., Orsulic, S., Karlan B. Y., & Walsh C. S. (2012). Xeroderma Pigmentosum Complementation Group C Single-Nucleotide Polymorphisms in the Nucleotide Excision Repair Pathway Correlate With Prolonged Progression-Free Survival in Advanced Ovarian Cancer. Cancer, 118, 689-697.

Liu Z, Beach JA, Agadjanian H, Jia D., Aspuria P, Karlan BY, Orsulic S. (2016). Abstract B64: Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B64

Taylor-Harding B, Agadjanian H, Aspuria P, Cheon, D., Mizuno T, Greenberg D, Allen JR, Orsulic S, Walsh C, Karlan BY, Wiedemeyer WR. (2014). Abstract 678: The Ets factor ETV5 regulates E2F target genes and mediates drug resistance Cancer Research. 74: 678-678. DOI: 10.1158/1538-7445.Am2014-678

Agadjanian H, Cheon D., Diaz E, Laury A, Miller C, Karlan B, Orsulic S, Walsh C. (2013). Abstract 329: A mouse model of epithelial ovarian cancer with defined oncogenic drivers. Cancer Research. 73: 329-329. DOI: 10.1158/1538-7445.Am2013-329

Taylor-Harding B, Agadjanian H, Orsulic S, Walsh C, Karlan BY, Wiedemeyer W. (2013). Abstract 1749: Cell cycle requirements shape ovarian cancer progression. Cancer Research. 73: 1749-1749. DOI: 10.1158/1538-7445.Am2013-1749

Taylor-Harding B, Agadjanian H, Aspuria PJ, Mizuno T, Cheon D., Orsulic S, Karlan B, Walsh C, Wiedemeyer WR. (2013). Abstract B48: Targeting chemo-resistance in CCNE1-amplified ovarian cancer Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B48

Walsh, C., Nassanian, H., Agadjanian, H., Miller, C., Orsulic, S., & Karlan, B. (2015).
Abstract BIOL-1348. No association between PARK2 and BRCA1-associated gynecologic cancers. Cancer Research, 21(16 Supplement): POSTER-BIOL-1348. DOI:10.1158/1557-3265.OVCASYMP14

Taylor-Harding, B., Agadjanian, H., Aspuria, P-J., Mizuno, T., Cheon, D-J., Orsulic, S., Karlan, B., Walsh, C., & Wiedemeyer, W.R. (2014). Abstract B48. Targeting chemo-resistance in CCNE1-amplified ovarian cancer. Clinical Cancer Research, 19, B48.

Agadjanian, H., Cheon, D-J, Diaz, E., Laury, A., Miller, C., Orsulic, S., & Walsh C. (2013). Abstract 329. A mouse model of epithelial ovarian cancer with defined oncogenic drivers. Cancer Research, 73(8 supplement) p.329.

Taylor-Harding, B., Agadjanian, H., Orsulic, S., Walsh, C., Karlan, B., & Wiedemeyer, W.R. (2013). Abstract 1749. Cell Cycle requirements shape ovarian cancer progression. Cancer Research, 73, p.1749.